Tired Of Nutlin-3a... Then Simply Read This!

Allergy 2011; 66: 686�C693. Background:? Intranasal corticosteroids (INSs) are a mainstay of treatment of allergic rhinitis (AR) nasal symptoms. The INS mometasone Pomalidomide mouse furoate nasal spray (MFNS) has well-documented efficacy and safety for the treatment and prophylaxis of nasal symptoms of seasonal AR (SAR) and for the treatment of nasal symptoms of perennial AR (PAR). Increasing interest has focused on whether INSs, including MFNS, may have beneficial effects on the ocular symptoms frequently associated with AR. Methods:? We performed a meta-analysis of 10 randomized, placebo-controlled trials of the efficacy of MFNS 200?mcg daily in relieving ocular allergy symptoms, including itching/burning, redness, and tearing/watering Nutlin-3a in vitro in both SAR and PAR. Four PAR studies and six SAR studies are included in the analysis. A fixed-effect inverse variance model was used to calculate weighted mean differences, 95% confidence intervals (CIs) for each comparison, and a combined overall treatment effect (Z) with P-value. Results:? In both analyses of SAR and PAR studies, including 3132 patients, all individual ocular symptoms were reduced in patients treated with MFNS. Overall treatment effect was significant for all three individual ocular symptoms in the SAR studies (Z?=?9.18 for tearing, Z?=?10.15 for itching, and Z?=?8.88 for redness; P?Oxymatrine placebo-controlled trials of MFNS for the treatment of AR provides level Ia evidence of its efficacy in treating nasal and non-nasal symptoms in SAR and PAR (7). Increasing interest has focused on whether INSs, including MFNS, may have beneficial effects in reducing the ocular symptoms frequently associated with AR (8). The eye is particularly susceptible to AR symptoms (itching [pruritis], redness [erythema], and tearing [epiphoria]) because it lacks a mechanical barrier to prevent the deposition of allergens, such as pollen, on the conjunctival surface (9).